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Abstract Thalidomide with melphalan/prednisone (MPT)
was defined as standard treatment in elderly patients with
multiple myeloma (MM) based on five randomized trials. In
one of these trials, HOVON49, a prospective health-related
quality-of-life (HRQoL) study was initiated in order to assess
the impact of thalidomide on QoL. Patients aged >65 years
with newly diagnosed MM were randomized to receive
melphalan plus prednisone (MP) or MPT, followed by
thalidomide maintenance in the MPT arm. Two hundred
eighty-four patients were included in this side study (MP, n=
149; MPT n=135). HRQoL was assessed with the EORTC
Core QoL Questionnaire (QLQ-C30) and the myeloma-
specific module (QLQ-MY24) at baseline and at predeter-
mined intervals during treatment. The QLQ-C30 subscales
physical function (P=0.044) and constipation (P<0.001)
showed an improvement during induction in favour of the
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MP arm. During thalidomide maintenance, the scores for the
QLQ-MY24 paraesthesia became significantly higher in the
MPT arm (P<0.001). The QLQ-C30 subscales pain (P=
0.12), insomnia (P=0.068), appetite loss (P=0.074) and the
QLQ-MY24 item sick (P=0.086) scored marginally better
during thalidomide maintenance. The overall QoL-scale
QLQ-C30-HRQoL showed a significant time trend towards
more favourable mean values during protocol treatment
without differences between MP and MPT. For the QLQ-
C30 subscales emotional function and future perspectives,
difference in favour of the MPT arm from the start of
treatment was observed (P=0.018 and P=0.045, respectively)
with no significant ‘time×arm’ interaction, indicating a
persistent better patient perspective with MPT treatment.
This study shows that the higher frequency of toxicity
associated with MPT does not translate into a negative effect
on HRQoL and that MPT holds a better patient perspective.
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Introduction
Multiple myeloma (MM), a neoplasm of plasma cells, affects
6 per 100,000 individuals each year worldwide [1, 2]. It is a
progressive disease marked by increased risk of infections,
skeletal destruction (leading to bone pain and fractures),
renal failure and anemia [3]. Since the 1960s melphalan plus
prednisone (MP) was the standard treatment for elderly
patients (>65 years) with MM. However, the response
duration was rather short and the median survival about
3 years. Recently, five randomized clinical phase III trials in
which thalidomide was added to the melphalan/prednisone
schedule as first line treatment demonstrated a higher
response rate, a qualitative better response, increased
progression-free survival and in three out of five also a
benefit in overall survival [4–9]. Melphalan plus prednisone
and thalidomide (MPT) is now regarded as a new standard
for treatment of multiple myeloma in the elderly patient.
However, in all these trials, thalidomide was associated with
a higher incidence of adverse effects, such as deep-vein
thrombosis, peripheral neuropathy, constipation and infec-
tions (CTC 3/4). In contrast, the better treatment efficacy
leads to a reduction of MM-related symptoms. It is therefore
imperative to clarify to what extent both aspects, increased
efficacy and higher risk of adverse events, affect the quality
of life of patients. In the HOVON 49 trial comparing MP vs.
MPT followed by thalidomide maintenance in the MPT arm,
a prospective health-related quality-of-life (HRQoL) study
was integrated with the purpose of evaluating the impact of
thalidomide on patients’ quality of life [9]. Here, we report
the results of this assessment.
Methods
Study design and treatment
Details on the HOVON 49 study were recently published.
In summary, the HOVON 49 was a prospective phase III
randomized (1:1), open-label, multicenter trial that com-
pared standard melphalan plus prednisone with melphalan
plus prednisone and thalidomide for patients aged >65 years
with newly diagnosed symptomatic multiple myeloma.
Patients were included who had symptomatic MM, stage
Ib, II or III according to the Salmon and Durie criteria [10].
Treatment consisted of 8 cycles of melphalan 0.25 kg/kg
per day and prednisone 1 mg/kg per day for 5 days. Cycles
were given every 4 weeks. In the MPT arm, thalidomide
200 mg/daily was added. In case of disease progression or
non-response, patients should stop protocol treatment and
might start second-line treatment. Patients were allowed to
receive more than eight courses in case of ongoing response
until a plateau phase of M protein was achieved. Patients
randomized to the MPT arm and who reached the plateau
level of response received maintenance therapy of thalido-
mide 50 mg/daily until progression or relapse.
During this trial treatment with bisphosphonates was
recommended, either pamidronate or clodronate. At the
start of this study, there were no guidelines on use of
thrombosis prophylaxis. Low molecular weight heparin was
recommended as standard during MPT treatment from 2005
on, and during maintenance, low-dose aspirin was advised
[9, 11]. The study was conducted according to the
Declaration of Helsinki and the guidelines of good clinical
practice. The trial was registered as ISRCTN90692740.
Patients
In principle, the HRQoL study included all clinically
evaluable patients who participated in the HOVON 49
study. For this analysis, those patients were included for
whom at least one valid HRQoL assessment was available,
either at baseline or during the treatment trajectory.
HRQoL questionnaires
In this study two validated questionnaires were used:
European Organization for Research and Treatment of
Cancer (EORTC) QLQ-C30 and the EORTC QLQ-MY24.
The QLQ-C30 is a multidimensional, cancer-specific,
quality-of-life questionnaire developed by the EORTC
Study Group on Quality of Life for use in international
clinical trial settings [12]. It includes five functional scales
(physical, role, emotional, social and cognitive function-
ing), three symptom scales (fatigue, pain, and nausea and
vomiting), a global health status/quality-of-life scale and a
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number of single items assessing additional symptoms
(dyspnoea, sleep disturbance, constipation and diarrhoea)
and perceived financial impact. For the majority of the
QLQ-C30 items, a four-point Likert-type response scale is
used. Exceptions are the items for the global quality-of-life
scale (where a seven-point scale is used). The EORTC
QLQ-MY24 questionnaire measures specific aspects that
are relevant for the quality of life (QoL) in multiple
myeloma patients. The questionnaire contains the following
scales: pain, side effects of treatment, social support, body
image and future perspectives [13].
The patients’ individual score of each subscale was
calculated as the sum and the mean of the available items
for that scale. All subscale responses were linearly
converted to 0–100 scales. For the functional and global
quality-of-life scales, a higher score represents a better level
of functioning. For the symptom scales and items, a higher
score reflects a greater degree of symptomatology. If the
number of missing items for a certain scale was less than
half of the number of needed items for that scale, the score
was calculated on the basis of the available items.
Otherwise, the whole scale was coded as missing.
Data collection
According to the study protocol, QoL should be measured
at the following time points:
1. At study entry, prior to the first cycle (‘baseline’)
2. After cycle 3, approximately at 3 months after the start
of cycle 1
3. After cycle 8, approximately at 9 months after the start
of cycle 1
4. At 12 months after start cycle 1
5. At 18 months after start cycle 1
After obtaining informed consent, the baseline question-
naire was handed out by the QoL coordinator of the
participating hospital. The subsequent questionnaires were
sent to the patient by the HOVON data centre with a pre-
stamped reply envelope to facilitate returning. If the patient
refused to transmit his/her address to the HOVON data
centre, all questionnaires were handed out and returned by
the QoL coordinator. The QoL coordinator received a
reminder email in time in order to hand out the question-
naire at the correct time point.
Statistical analysis
Definition of discrete treatment trajectory time points
Variation between patients in the number of received cycles of
melphalan/prednisone was present. The 3-month, 8-month
and 12-month questionnaires as indicated in the study
protocol may represent the induction phase, end of treatment
or late follow-up according to the individual patient his/her
unique treatment trajectory. In order to keep the comparison
between the two randomization arms unconfounded by the
actual phase of the treatment protocol, the time points of QoL
assessment were categorized in four broad classes: at study
entry before the start of the first cycle or within 3 days
thereafter (baseline ‘t0’), during or shortly after (within a
week) the phase of induction treatment (induction ‘i.’), during
the period following the first week after induction treatment
until the start of the next treatment off protocol (post-induction
‘p.’), and after progression, relapse or starting a next treatment
off protocol (re-treatment ‘r.’).
To include a maximum number of returned question-
naires in the analysis, the dates of filling out the
questionnaires were categorized according to the number
of months after the start of cycle 1 for the induction and
post-induction phases separately. For induction (i.) these
time points were: ‘i. months 1–2’, ‘i. month 3’, ‘i.
months 4–7’ and ‘i. ≥8 months’. For post-induction these
time points were: ‘i. <12 months’ (prior to the indicated
ranges below in case of early stopping of induction
treatment), ‘i. 12 months’ (range 10.8–15.8) and ‘i.
18 months’ (range 15.8–21.3). No subdivision in time
points was made for those questionnaires that were filled
out after relapse, progression or starting a new treatment off
protocol (r.).
Statistical model
To obtain estimates of the mean scores for the EORTC
QLQ-C30 and QLQ-MY24 subscales that might be
regarded as continuously distributed outcome variables at
each of the above described discrete treatment trajectory
time points, a linear mixed model was used with a random
intercept for patient effects and time according to the
protocol trajectory (categorical), arm of randomization and
their interaction as fixed effects. The subscales that were
based on a single item, and thus, had a multinomial
distribution, were likewise analyzed using (ordinal) logistic
regression with a random intercept.
The estimated effect of arm of randomization without
taking the interaction between treatment trajectory time and
arm into account is indicative of the difference between the
two arms already present at baseline and, hence, should be
zero in case of perfect randomization. The estimated
interaction effects between treatment trajectory time and
arm of randomization are indicative of the effect of arm in
addition to the (possible) difference by arm already present
at baseline and, hence, might be assigned to the additional
treatment with thalidomide in the experimental arm. Tests
were performed using the Wald’s test for different linear
combinations of estimated parameters. The mean of a
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continuously EORTC QLQ-C30 or QLQ-MY24 subscale
for a certain treatment trajectory time point and arm of
randomization was calculated as the sum of the intercept,
the estimated effect parameter for arm of randomization, the
appropriate effect parameter for treatment trajectory time
point and the appropriate effect parameter for interaction
between time and arm of randomization. The estimated
proportion of patients with an answer in a certain category
of a mono-item subscale (i.e. a multinomial distributed
subscale) was likewise calculated by arm of randomization
and treatment trajectory time point on the basis of the
estimated effect parameters.
The results of a selection of subscale were graphically
displayed together with the P values and degrees of
freedom of the Wald’s tests.
Next to time, arm and terms for interaction between time
and arm, last registered response (≥PR vs. <PR) prior to a
certain HRQoL assessment and toxicity as registered during
the same time interval of the treatment trajectory were included
in the multivariate model. Toxicity was defined as any dose
reduction or discontinuation of melphalan, prednisone or
thalidomide during induction or maintenance due to side
effects. In this way, it was assessed whether response and
toxicity were associated with the HRQoL, either in favourable
or unfavourable sense, and whether the above described results
on time, arm and interaction between both were modified
when these factors were included in the multivariate model.
The data of all patients with at least one HRQoL
assessments, either at baseline, during treatment or during
follow-up, were included in the analysis. Random-intercept
models make it possible to include the data of patients with
missing data as well. Those patients with only one QoL
assessment contribute to the location of the intercept and to
differences by randomization arm.
All analyses were performed with STATA statistical
software, version 10.1 (StataCorp., TX, USA).
Results
Patient characteristics
The HOVON 49 MM trial accrued 344 patients from 58
centres between 2002 and 2007. Median follow-up at the time
of last contact was 3.25 years. Of the 333 eligible patients, 284
participated in the prospective HRQoL side study, of whom
149 were randomized to receive MP and 135 MPT. No
significant differences in clinical characteristics were present
between participants and non-participants. The clinical char-
acteristics of participating patients are shown by arm of
randomization in Table 1.
At baseline, the mean EORTC scores were comparable
between MP and MPT, except for emotional function,
future perspectives, social support and global health and
QoL subscale (P=0.018, P=0.045, P=0.032 and P=0.050
respectively), which were in favour of MPT (Table 2).
Patient functioning by treatment trajectory time point
and arm of randomization
Continuously distributed subscales
For the overall QLQ-C30 global health status subscale (QLQ-
C30-HR-QOL), a significant time trend towards higher—
more favourable—mean values during the protocol treatment
trajectory was observed but no differences between MP and
MPT could be established [Fig. 1 (1.1)]. No significant
‘time×arm’ interaction effects were observed from induction
to post-induction and after progression/relapse indicating that
thalidomide had no effect on this subscale.
For the QLQ-C30 physical function subscale [Fig. 1
(1.2)], role function and emotional functioning [Fig. 1
(1.3)] statistically significant and favourable time trends
during protocol treatment were found as well (P<0.001).
For the QLQ-C30 subscale physical function, a treatment-
related improvement in favour of the MP arm was found
early during induction phase, yielding a significant ‘time×
arm’ interaction effect during induction (P=0.044). During
post-induction and after starting a new treatment, no
significant differences by arm of randomization were
observed anymore.
For the QLQ-C30 emotional function subscale [Fig. 1
(1.3)] as well as for the QLQ-MY24 future perspective
subscale [Fig. 1 (1.6)], a difference in favour of the MPT
arm during the complete treatment trajectory was observed.
However, these differences were already present at baseline
(P=0.018 and P=0.045, respectively) and, hence, no
significant ‘time×arm’ interaction could be established,
indicating a persistent better patient perspective with MPT
treatment.
For the QLQ-MY24 side effects subscale no differences
between the two arms, neither at baseline, nor during
protocol treatment and during follow-up was found. After
looking into detail of the different items of this MY24
subscale, however, highly significant terms for interaction
during post-induction (‘p.’) and after progression/relapse or
starting a new treatment (‘r.’) could be established for the
item paraesthesia in favour of the MP arm [Fig. 1 (1.8)]. No
differences between the two arms were found at baseline
and during early induction (P=0.69 and P=0.66, respec-
tively) but after 3 months, higher scores were found in the
MPT arm which became significant during post-induction
and after progression/relapse or starting a new treatment off
protocol (P<0.001).
For the item sick, (borderline) significant terms for
interaction during post-induction and after progression/
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relapse or starting a new treatment in favour of the MPT
arm were found [P=0.086 and P=0.027, respectively;
Fig. 1 (1.7)].
For the other items of the dimension side effects, no
differences in favour of either the MP or MPT arm were
found.
For the QLQ-MY24 social support subscale, significant
differences between the two arms were present, both at
baseline (P=0.032) and during the protocol treatment
trajectory (induction, P=0.02; post-induction, P=0.024).
However, the differences were not unequivocal in favour of
either MP or MPT, thus, a closely reasoned argument is
Table 1 Baseline characteristics QoL participation MP arm vs. MPT arm
MP (no. and percentage) MPT (no. and percentage) Total (no. and percentage)
Total 149 100% 135 100% 284 100%
Sex (P=0.641, χ2)
M 82 55% 78 58% 160 56%
F 67 45% 57 42% 124 44%
Age (P=0.345, t test)
Median 72 (65–84) 71 (65–83) 72 (65–84)
Age in three classes (P=0.249, χ2)
≤70 52 35% 60 44% 112 39%
71–75 50 34% 37 27% 87 31%
>75 47 32% 38 28% 85 30%
WHO status (P=0.101, χ2)
WHO 0 45 30% 59 44% 104 37%
WHO 1 76 51% 58 43% 134 47%
WHO 2 21 14% 15 11% 3 6 13%
WHO 3 7 5% 3 2% 10 4%
Stage of disease (Salmon & Durie (S&D)) (P=0.809, exact)
1B 0 1 1% 1 0%
2A 39 26% 32 24% 71 25%
2B 1 1% 2 1% 3 1%
3A 97 65% 87 64% 184 65%
3B 12 8% 13 10% 25 9%
International Staging System (ISS) (calculated) (P=0.454, exact)
Stage I 36 24% 37 27% 73 26%
Stage II 35 23% 37 27% 72 25%
Stage III 25 17% 25 19% 50 18%
Unknown 53 36% 36 27% 89 31%
M-protein heavy chain (P=0.839, exact)
IgA 43 24% 39 29% 82 29%
IgG 92 62% 80 59% 172 61%
IgD 0 1 1% 1 0%
LCD 14 9% 15 11% 29 10%
M-protein light chain (P=0.322, exact)
Kappa 99 66% 82 61% 181 64%
Lambda 49 33% 53 39% 102 36%
Unknown 1 1% 0 1 0%
Number of skeletal lesions (P=0.846, exact)
None 41 28% 39 29% 80 28%
Single 8 5% 7 5% 15 5%
2 lesions 9 6% 4 3% 13 5%
3+ lesions 88 59% 77 57% 165 58%
Unknown 3 2% 8 5% 11 3%
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1.1 QLQ-C30 Global health 1.2 QLQ-C30 Physical function
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QLQ-C30 pain
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hard to give. For the QLQ-C30 subscale cognitive function,
a borderline significant (P=0.052) interaction between arm
and time point during the post-induction phase was found.
However, these differences were not consistently in favour
of the MP or the MPT arm.
Subscales with multinomial distribution
In Fig. 2 the estimated proportions of patients with an answer
in a certain category of a mono-item subscale are shown by
arm of randomization and time point in the treatment
trajectory. The proportions for each time point and arm of
randomization separately sum up to 100%. For the graphs in
the Fig. 2 (2.1–2.3), the answer categories ‘Moderate’ and
‘Severe’ were taken together in one category because of small
numbers in these separate categories. For the same reason, for
the graph in Fig. 2 (2.4, body image), the categories ‘No’ and
‘Mild’ were taken together in one category.
For the QLQ-C30 subscales insomnia [Fig. 2 (2.1)],
appetite loss [Fig. 2 (2.2)] and constipation [Fig. 2 (2.3)], a
favourable time trend towards higher percentages of patients
without these symptoms (P=0.058, P=0.001 and P=0.002,
respectively) was established in both arms. For constipation
a significant ‘time×arm’ interaction effect (P<0.001) was
found during induction, associated with higher percentages
of patients with this symptom in the MPT arm. During post-
induction, a borderline significant ‘time×arm’ interaction
was found in favour of the MPT arm for insomnia (P=0.068)
and appetite loss (P=0.074), indicating more favourable
percentages of patients without this symptom in the MPT
arm. For appetite loss this continued after progression/relapse
or starting a new treatment (P=0.006).
For the QLQ-MY24 body image subscale [Fig. 2
(2.4)], a significant ‘time×arm’ interaction during post-
induction (P=0.009) was established associated with an
unfavourable time trend towards a higher percentage of
patients in the symptom category ‘severe’ in the MPT
arm. After starting a new treatment, no difference in
percentages between the two arms was found (P=0.36,
Table 3).
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QLQ-MY24 MM body image
2.1 QLQ-C30 Insomnia 2.2 QLQ-C30 Appetite loss 
2.3 QLQ-C30 Constipation 2.4 QLQ-MY24 Body image
Fig 2 Comparison of QoL parameters during therapy withMP orMPT in patients with multiple myeloma (gray lines MP, black lines MP+thalidomide).
Output from ordinal logistic regression
Fig 1 Comparison of QoL parameters during therapy with MP or
MPT in patients with multiple myeloma (gray lines MP, black lines
MP+thalidomide). Output from linear mixed model
R
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Inclusion of response and toxicity data in the multivariate
models
Continuously distributed subscales
A favourable response (at least PR) was (borderline)
significantly associated with more favourable scores on
the QoL-C30 dimensions: global health, physical function,
role function, emotional function, social function, fatigue,
nausea/vomiting, pain and the MY24-dimensions pain, side
effects and future perspectives. The only significant
association with toxicity that caused dose reduction or
discontinuation was with the dimension role function, and
this was in unfavourable direction (i.e. more toxicity gave a
lower score for role function).
For a number of these dimensions, the time trend
towards more favourable scores disappeared or became
less pronounced, e.g. QLQ-C30 dimensions global health,
physical function, and emotional function. This finding
suggests that the favourable time trend along the treatment
trajectory is strongly associated with the appearance of a
favourable response on therapy. However, no substantial
influence of adjustment for response and toxicity on the
effect of arm or on the arm×time interactions was found,
which implies that comparison between the two arms is not
confounded by either response or toxicity.
Subscales with multinomial distribution
Both a favourable response (≥PR) and the presence of
toxicity leading to dose reduction or discontinuation were
unfavourably and significantly associated with a higher
score on the QLQ-C30 dimension dyspnoea. For the
dimensions insomnia and appetite loss, a favourable
Table 3 QoL by dimension, arm of randomization (MP vs. MPT) and time point in treatment trajectory
Induction (i.) Post-induction (p.) After re-treatment/relapse/
progression (r.)
QoL dimension t0 (baseline) i. >8 months p. <12 months p. 18 months r. (off protocol)
Arm
QLQ-C30 dyspnoea mild/severe (%) MP 32.7/17.5 35.4/25.1 33.4/19.0 29.4/13.0 35.0/23.5
MPT 34.2/20.8 30.1/13.7 35.6/26.4 31.7/15.8 34.9/22.9
P value time point=0.18 (df=8),
P value arm=0.42 (df=1), P value arm×time= 0.11 (df=4) 0.36 (df=3) 0.38 (df=1)
QLQ-C30 insomnia mild/severe (%) MP 30.8/25.9 26.3/15.4 24.9/13.5 26.5/15.7 23.8/12.3
MPT 29.7/21.8 21.9/10.4 22.9/11.3 23.8/12.3 26.2/15.2
P value time point=0.002 (df=8),
P value arm=0.38 (df=1), P value arm×time= 0.29 (df=4) 0.68 (df=3) 0.14 (df=1)
QLQ-C30 appetite loss mild/severe (%) MP 26.4/24.6 13.3/6.0 20.7/13.1 19.3/11.4 22.7/15.8
MPT 26.6/25.8 18.9/11.0 19.5/11.6 7.7/2.6 14.5/6.9
P value time point=0.002 (df=8),
P value arm=0.84 (df=1), P value arm×time= 0.88 (df=4) 0.74 (df=3) 0.006 (df=1)
QLQ-C30 constipation mild/severe (%) MP 23.1/15.4 16.2/7.9 18.6/10.0 18.4/9.8 22.8/15.0
MPT 24.9/18.5 24.9/18.6 23.3/15.7 20.6/12.2 24.0/16.8
P value time point=0.002 (df=8),
P value arm=0.43 (df=1), P value arm×time= <0.001 (df=4) 0.72 (df=3) 0.79 (df=1)
QLQ-C30 diarrhoea mild/severe (%) MP 12.2/45.8 14.8/6.2 13.7/5.4 11.9/4.3 16.8/7.6
MPT 13.4/5.3 8.5/2.7 12.1/4.5 9.2/3.0 14.8/6.2
P value time point=0.70 (df=8),
P value arm=0.70 (df=1), P value arm×time= 0.52 (df=4) 0.77 (df=3) 0.42 (df=1)
QLQ-C30 financial problems mild/severe (%) MP 10.2/3.5 16.8/8.6 12.5/5.2 14.2/6.6 16.8/8.7
MPT 7.8/2.1 10.1/3.3 9.0/2.7 10.3/3.5 12.3/4.9
P value time point=0.038 (df=8),
P value arm=0.33 (df=1), P value arm×time= 0.39 (df=4) 0.98 (df=3) 0.72 (df=1)
QLQ-C30 body image moderate/severe (%) MP 19.8/65.6 23.4/54.9 21.4/61.5 21.3/61.5 23.8/53.1
MPT 18.2/69.3 17.7/70.3 24.5/48.8 15.2/75.6 24.3/50.6
P value time point=0.25 (df=8),
P value arm=0.55 (df=1), P value arm×time= 0.78 (df=4) 0.009 (df=3) 0.36 (df=1)
Shown are the estimated percentages at baseline (t0), at the end of induction treatment (i. >8 months), at the start and at the end of the episode post-induction
(p. <12 months and p. 18 months) and after going off protocol (i.e. after starting a new treatment, relapse and/or progression). P values given: P value time
point; P value arm at baseline; P value interaction arm×time: episode of induction (i.), post-induction (p.) and after progression/re-treatment (r.)
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response (≥PR) appeared to be significantly associated with
a more favourable (i.e. lower) score on these dimensions.
For these dimensions, the time trend along the treatment
trajectory disappeared in terms of statistical significance
after adjustment for response and toxicity. As was the case
with the continuously distributed subscales, no substantial
influence of adjustment for response and toxicity on the
effect of arm or on the arm×time interactions was found,
which implies that comparison between the two arms is not
confounded by either response or toxicity.
Inclusion of gender and hemoglobin data in the multivariate
models
Similar results were found when effects where adjusted for
gender and hemoglobin at baseline.
For both gender and hemoglobin at baseline, no
influence of adjustment on the effect of arm or on the
arm×time interactions was found.
When looking at the different QoL dimensions, we
observed, on average, that the QoL scores for females were
more unfavourable compared to males. For example, for
females, an unfavourable higher mean score was found for
the scales nausea/vomiting (β-coefficient 5.37; P=0.001),
appetite loss (β-coefficient 2.06; P=0.020), as well as for
specific side effects of myeloma treatment (β-coefficient
3.80; P=0.019). Females also reported unfavourable lower
scores for physical functioning (β-coefficient −7.87; P=
0.003), emotional functioning (β-coefficient −4.74; P=
0.039), social functioning (β-coefficient −6.51; P=0.018)
and future perspectives (β-coefficient −6.06; P=0.026), but
for all these items, inclusion of gender in the model did not
modify the arm effect nor the interaction arm×time effects.
Discussion
Combining clinical outcomes of a treatment with assess-
ment of the impact of this treatment on HRQoL provides
additional value for evaluating treatment effects [14].
Systematic incorporation of HRQoL measures into clinical
trials allows for a comparison of treatment arms that
includes the patients’ perspective. A review study of Kvam
et al. in 2009 showed that there are few randomized clinical
trials in MM that include HRQoL as a study end-point [15].
HOVON 49 is, to our knowledge, the first phase III
randomized multicenter trial comparing the efficacy of MP
vs. MPT combined with a HRQoL assessment.
Treatment with MPT not only showed increased efficacy
but also higher frequency of toxicity associated with MPT.
The main objective of this study was to evaluate the effect
of thalidomide on the quality of life for elderly patients with
multiple myeloma. Our study shows that treatment resulted
in improvement of the scores on overall global health,
fatigue, pain, side effects, isomnia and appetite loss in both
the MP and the MPT arm. For the subscales pain, insomnia
and appetite loss, differences even in favour of the MPT
arm were observed.
However, MPT was associated with a significant
increase in paraesthesia from post-induction onwards.
Increase of these symptoms after 8 months of treatment is
consistent with a cumulative dose-dependent effect of
thalidomide [9, 16]. This underscores the need for dose
reductions and limited periods of maintenance therapy [16,
17]. In spite of the higher incidence of some toxicities with
MPT compared to MP (that is constipation and paraesthe-
sia), this is not reflected in the overall quality-of-life scale
QLQ-C30-HRQoL. No unfavourable overall difference in
self-reported side effects (QLQ-MY24) between the two
arms was observed during the study protocol either. The
mean score on the item about feeling sick became even
significantly lower in the MPT arm compared to the MP
arm during post-induction.
Clinical significance
A prospective study by Kvam et al. determined the clinical
significance of changes in EORTC QLQ-C30 scores in
patients with MM by identifying the smallest difference that
matters: the so-called minimally important difference. They
concluded that a difference of 6–17 points represents a
meaningful change in improvement or deterioration in
patients and that only score differences equally or greater
than this should be used for treatment recommendations [18].
When applying this definition to our results, it can be
concluded that a clinical significant difference was observed
for the subscales global health, role functioning, emotional
functioning, social functioning, fatigue and pain at the end of
post-induction (P=18 months) in favour of the MPT-treated
patients compared to MP.
An important strength of this study is the use of a
prospective design. We were able to assess the effect of
thalidomide on the QoL at different time points during
treatment trajectory allowing to differentiate according to
stage of treatment. Another strength of our study is the use
of a statistical model for repeated measurements, as was
also employed in a study on QoL among patients with
endometrial cancer [19]. This model makes it possible to
include all QoL assessments, as the correlation between
measurements from the same patient is taken into account,
and the data of patients with missing data on QoL
assessments contribute to the estimations as well. This
model makes it possible to make a clear distinction between
differences between the two arms of randomization already
present at baseline and those that may have been caused by
the additional treatment with thalidomide after starting the
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induction treatment by inclusion of terms for (time×arm)
interaction. An example is the differences observed
between the two randomization arms with respect to QoL
scores for the dimensions emotional functioning and future
perspective. Both of these differences were already present
at baseline and no significant (time×arm) interaction could
be established. Given the random assignment of the
treatment arms and the fact that the two groups were well
balanced for clinical characteristics, these differences may
indicate a persistent better patient perspective with MPT
treatment. Since the first questionnaire was filled out prior
to treatment but after randomization, we hypothesise that
the awareness of being treated with a medication that holds
out a prospect of better treatment outcome may in itself be
associated with improved feeling of well-being and hope
for the future. Another explanation for these findings may
be found in the so-called Hawthorne effect. Patients
perform better when they know they are under observation
for an intervention. Patients receiving the experimental
(MPT) treatment might feel more special and therefore
score better on both subscales from baseline on forward
than patients receiving the standard treatment.
The study has also some limitations. First, not all
patients included in the HOVON 49 trial participated and
the most burdened patients are the ones least likely to
participate. However, this is inherent to each QoL survey.
Secondly, while the patients were evaluated during prede-
termined time points during induction and post-induction
treatment, not all patients filled out the questionnaire at the
exact same time. This problem was overcome by grouping
the results into well-defined phases. Finally, the results do
not take into account all potential comorbidities of the
patients enrolled in this study. As the QoL assessments
were part of a RCT, this does not jeopardise the primary
conclusion of the present. There may be different effects of
treatment with thalidomide on HRQoL in different sub-
groups defined on the basis of comorbidities. Such a
subgroup analysis should be based on clear a priori
hypotheses and might require an additional study and data
collection.
In conclusion, this prospective study shows that the
higher frequency of adverse effects associated with MPT
does not translate into a negative effect on the HRQoL as
reported by patients and that MPT holds a better patient
perspective. This can be interpreted as a favourable result
because the current standard treatment of MPT for elderly
patients with MM is not only known to have an improved
clinical outcome but also no reduction in HRQoL.
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